Show simple item record

dc.contributor.authorHaass, Nikolas K
dc.contributor.authorGabrielli, Brian
dc.date.accessioned2021-10-17T04:46:58Z
dc.date.available2021-10-17T04:46:58Z
dc.date.issued2017
dc.identifier.issn0906-6705
dc.identifier.doi10.1111/exd.13303
dc.identifier.urihttp://hdl.handle.net/10072/409123
dc.description.abstractThe advent of targeted therapies of metastatic melanoma, such as MAPK pathway inhibitors and immune checkpoint antagonists, has turned dermato-oncology from the “bad guy” to the “poster child” in oncology. Current targeted therapies are effective, although here is a clear need to develop combination therapies to delay the onset of resistance. Many antimelanoma drugs impact on the cell cycle but are also dependent on certain cell cycle phases resulting in cell cycle phase-specific drug insensitivity. Here, we raise the question: Have combination trials been abandoned prematurely as ineffective possibly only because drug scheduling was not optimized? Firstly, if both drugs of a combination hit targets in the same melanoma cell, cell cycle-mediated drug insensitivity should be taken into account when planning combination therapies, timing of dosing schedules and choice of drug therapies in solid tumors. Secondly, if the combination is designed to target different tumor cell subpopulations of a heterogeneous tumor, one drug effective in a particular subpopulation should not negatively impact on the other drug targeting another subpopulation. In addition to the role of cell cycle stage and progression on standard chemotherapeutics and targeted drugs, we discuss the utilization of cell cycle checkpoint control defects to enhance chemotherapeutic responses or as targets themselves. We propose that cell cycle-tailored targeting of metastatic melanoma could further improve therapy outcomes and that our real-time cell cycle imaging 3D melanoma spheroid model could be utilized as a tool to measure and design drug scheduling approaches.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherJohn Wiley & Sons
dc.relation.ispartofpagefrom649
dc.relation.ispartofpageto655
dc.relation.ispartofissue7
dc.relation.ispartofjournalExperimental Dermatology
dc.relation.ispartofvolume26
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsDermatology
dc.subject.keywordscell cycle
dc.subject.keywordsdrug resistance
dc.titleCell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationHaass, NK; Gabrielli, B, Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities, Experimental Dermatology, 2017, 26 (7), pp. 649-655
dcterms.dateAccepted2017-01-18
dc.date.updated2021-10-17T04:45:39Z
gro.hasfulltextNo Full Text
gro.griffith.authorGabrielli, Brian


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record